Fortrea Holdings (FTRE) Cash from Investing Activities (2022 - 2026)
Fortrea Holdings (FTRE) reported Cash from Investing Activities of -$8.0 million for Q1 2026, down 149.69% on a YoY basis from $16.1 million in Q1 2025, and down 6.67% quarter-over-quarter from -$7.5 million in Q4 2025.
Fortrea Holdings (FTRE) Cash from Investing Activities (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Cash from Investing Activities for 5 years, with the latest figure at -$8.0 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities fell 149.69% year-over-year to -$8.0 million; the trailing twelve-month figure through Mar 2026 stood at -$9.7 million (down 103.5% YoY), and the FY2025 full-year result was $14.4 million, down 94.28% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$8.0 million, down from -$7.5 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $265.4 million in Q2 2024, with the low at -$18.4 million in Q4 2022.
- Historically, Cash from Investing Activities has averaged $12.7 million across 5 years, with a median of -$8.0 million in 2026.
- The largest YoY upside for Cash from Investing Activities was 2953.76% in 2024 against a maximum downside of 400.0% in 2024.
- Fortrea Holdings' Cash from Investing Activities stood at -$18.4 million in 2022, then jumped by 51.09% to -$9.0 million in 2023, then soared by 138.89% to $3.5 million in 2024, then sank by 314.29% to -$7.5 million in 2025, then slipped by 6.67% to -$8.0 million in 2026.
- The last three Cash from Investing Activities figures came in at -$8.0 million (Q1 2026), -$7.5 million (Q4 2025), and $13.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | -8.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.00 Mn |
| Mar 31, 2026 | -8.00 Mn |
| Dec 31, 2025 | -7.50 Mn |
| Dec 31, 2025 | -7.50 Mn |
| Sep 30, 2025 | 13.30 Mn |
| Sep 30, 2025 | 13.30 Mn |
| Jun 30, 2025 | -7.50 Mn |
| Jun 30, 2025 | -7.50 Mn |
| Mar 31, 2025 | 16.10 Mn |
| Mar 31, 2025 | 16.10 Mn |
| Dec 31, 2024 | 3.50 Mn |
| Dec 31, 2024 | 3.50 Mn |
| Sep 30, 2024 | -8.10 Mn |
| Sep 30, 2024 | -8.10 Mn |
| Jun 30, 2024 | 265.40 Mn |
| Jun 30, 2024 | 265.40 Mn |
| Mar 31, 2024 | -9.20 Mn |
| Mar 31, 2024 | -9.20 Mn |
| Dec 31, 2023 | -9.00 Mn |
| Dec 31, 2023 | -9.00 Mn |